These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43 related articles for article (PubMed ID: 22797389)
1. Clinical studies in the second line setting of advanced pancreatic cancer: are we making any progress? Ramfidis VS; Strimpakos AS; Syrigos KN; Saif MW JOP; 2012 Jul; 13(4):358-60. PubMed ID: 22797389 [TBL] [Abstract][Full Text] [Related]
2. Any progress in the management of advanced pancreatic cancer? Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009. Li J; Saif MW JOP; 2009 Jul; 10(4):361-5. PubMed ID: 19581735 [TBL] [Abstract][Full Text] [Related]
3. New therapeutic strategies in the second line setting of advanced or metastatic pancreatic adenocarcinoma. Ramfidis VS; Syrigos KN; Saif MW JOP; 2013 Jul; 14(4):344-6. PubMed ID: 23846924 [TBL] [Abstract][Full Text] [Related]
4. Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin. Prescrire Int; 2005 Dec; 14(80):230-3. PubMed ID: 16400749 [TBL] [Abstract][Full Text] [Related]
5. First-line treatment for advanced pancreatic cancer. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011. Oberstein PE; Saif MW JOP; 2011 Mar; 12(2):96-100. PubMed ID: 21386629 [TBL] [Abstract][Full Text] [Related]
6. FOLFOX-6 combination as the first-line treatment of locally advanced and/or metastatic pancreatic cancer. Ghosn M; Farhat F; Kattan J; Younes F; Moukadem W; Nasr F; Chahine G Am J Clin Oncol; 2007 Feb; 30(1):15-20. PubMed ID: 17278889 [TBL] [Abstract][Full Text] [Related]
7. [Advances in research on capecitabine as adjuvant treatment for colon cancer after radical resection]. Zhang SZ Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):801-3. PubMed ID: 21223682 [No Abstract] [Full Text] [Related]
8. Oxaliplatin, 5-fluorouracil, and leucovorin as second-line treatment for advanced pancreatic cancer. Novarino A; Satolli MA; Chiappino I; Giacobino A; Bellone G; Rahimi F; Milanesi E; Bertetto O; Ciuffreda L Am J Clin Oncol; 2009 Feb; 32(1):44-8. PubMed ID: 19194124 [TBL] [Abstract][Full Text] [Related]
9. Can capecitabine replace 5-FU/leucovorin in combination with oxaliplatin for the treatment of advanced colorectal cancer? Twelves C Oncology (Williston Park); 2002 Dec; 16(12 Suppl No 14):23-6. PubMed ID: 12520636 [TBL] [Abstract][Full Text] [Related]
10. Current role of bevacizumab in colorectal cancer. Saltz L Clin Adv Hematol Oncol; 2009 Jun; 7(6):375-6. PubMed ID: 19606071 [No Abstract] [Full Text] [Related]
11. [Treatment of advanced gastric cancer with oxaliplatin plus 5-fluorouracil/ leucovorin (FOLFOX-4 chemotherapy)]. Garrido M; Melgoza G; Galindo H; Madrid J; Sánchez C; Nervi B; Alvarez M; Orellana E Rev Med Chil; 2007 Nov; 135(11):1380-7. PubMed ID: 18259648 [TBL] [Abstract][Full Text] [Related]
12. Unity is strength: one, two, or more drugs against advanced pancreatic cancer? Reni M; Cereda S; Belli C; Villa E Ann Oncol; 2011 Apr; 22(4):987. PubMed ID: 21289365 [No Abstract] [Full Text] [Related]
13. Second line treatment options for pancreatic cancer. Passero FC; Saif MW Expert Opin Pharmacother; 2017 Oct; 18(15):1607-1617. PubMed ID: 28820270 [TBL] [Abstract][Full Text] [Related]
14. Cancer of the pancreas: are we making progress? A review of studies in the US Oncology Research Network. Cartwright T; Richards DA; Boehm KA Cancer Control; 2008 Oct; 15(4):308-13. PubMed ID: 18813198 [TBL] [Abstract][Full Text] [Related]
15. Clinical and laboratory biomarkers in the management of pancreatic adenocarcinoma. Strimpakos AS; Syrigos KN; Saif MW JOP; 2012 Jul; 13(4):338-41. PubMed ID: 22797384 [TBL] [Abstract][Full Text] [Related]
16. Novel agents and new combination treatments on phase I studies on solid tumors and pancreatic cancer. Strimpakos AS; Syrigos KN; Saif MW JOP; 2012 Jul; 13(4):345-8. PubMed ID: 22797386 [TBL] [Abstract][Full Text] [Related]
17. Is there a role for herbal medicine in the treatment of pancreatic cancer?. Highlights from the "44th ASCO Annual Meeting". Chicago, IL, USA. May 30 - June 3, 2008. Saif MW JOP; 2008 Jul; 9(4):403-7. PubMed ID: 18648130 [TBL] [Abstract][Full Text] [Related]
18. The antisense oligonucleotide trabedersen (AP 12009) for the targeted inhibition of TGF-β2. Jaschinski F; Rothhammer T; Jachimczak P; Seitz C; Schneider A; Schlingensiepen KH Curr Pharm Biotechnol; 2011 Dec; 12(12):2203-13. PubMed ID: 21619536 [TBL] [Abstract][Full Text] [Related]
19. Risk determination for pancreatic cancer. Toki MI; Syrigos KN; Saif MW JOP; 2014 Jul; 15(4):289-91. PubMed ID: 25076322 [TBL] [Abstract][Full Text] [Related]
20. From trial highlights to clinical context: putting American Society of Clinical Oncology gastrointestinal news into practice. Aprile G; Lutrino SE; Sobrero A Future Oncol; 2013 May; 9(5):645-8. PubMed ID: 23647293 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]